Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma

Journal of B.U.ON.

Volumn 12, Issue 1, 2007, Pages 99-104

  Šorak, Marija ^a   Arsenijevic S ^a   Lukic G ^a   Arsenijevic N ^b   Ristic P ^b   Pavlovic S ^b   Popovic S ^b   Baskic D ^b  

^a Clinical Centre

^b UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

Benign ovarian tumors; Oncogenes; Ovarian carcinoma; Serum tumor markers; Tissue tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NUCLEOSIDE DIPHOSPHATE KINASE A; PROTEIN P53; TUMOR MARKER; NUCLEOSIDE DIPHOSPHATE KINASE; TP53 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; BENIGN TUMOR; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; OVARY CARCINOMA; OVARY TUMOR; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCORING SYSTEM; BLOOD; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROGNOSIS; UPREGULATION;

CA-125 ANTIGEN; CA-15-3 ANTIGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NUCLEOSIDE-DIPHOSPHATE KINASE; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 34249685640     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Berg JN, Lampe JG. High risk factors in gynecologic cancer. Cancer 1981; 48: 429-441.
2. Averette HE, Hoskins W, Nguyen HN et al. National survey of ovarian carcinoma: A patient care evaluation study of the American College of Surgeons. Cancer 1993; 71: 1629-1638.
3. Yarbro JW, Page DL, Fielding LP, Partridge EE, Murphy GP. American Joint Committee on Cancer prognostic factors consensus conference. Cancer 1999; 86: 2436-2446.
4. NIH Consensus Development Conference on Ovarian Cancer: Screening, treatment, and follow-up. Gynecol Oncol 1994; 55: S173.
5. Kanjuh V (Ed). General tumor pathology. Redakcija Medicinskog Podmlatka, Beograd, 1968 (in Serbian).
6. Gayther SA, Warren W, Mazoyer S et al. Germline mutation of the BRCA1 gene in breast and ovarian cancer families provides evidence for genotype-phenotype correlation. Nat Genet 1995; 11: 428-433.
7. Suzuki M, Saito S, Saga Y et al. Mutation of K-RAS protooncogene and loss of heterozygosity on 6q27 in serous and mucinous ovarian carcinomas. Cancer Genet Cytogenet 2000; 118: 132-135.
8. Harris C, Hollstein M. Clinical implications of the p53 tumor suppressor gene. NEJM 1993; 18: 1318-1327.
9. Pieretti M, Powell DE, Gattion HH, Case EA, Conway PS, Turker MS. Genetic atterations on chromosome 17 distinguish different types of epithelial ovarian tumors. Hum Pathol 1995; 26: 393-397.
10. Paik S, Hazan R, Fisher ER et al. Pathologic findings from the national surgical adjuvant breast and bowel project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103-109.
11. Gusterson B, Machin L, Gullick W et al. Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer. Int J Cancer 1988; 42: 842-849.
12. Simone G, Fatco G, Caponio MA et al. nm23 expression in malignant ascitic effusions of serous ovarian adenocarcinoma. Int J Oncol 2001; 19: 885-890.
13. Wu X, Zhang Z, Shi D. Nucleoside diphosphate kinase/nm23H1 expression in ovarian epithelial carcinoma: retroperitoneal lymphatic metastasis and survival. Zhonghua Yi Xue Za Zhi 1998; 78: 275-277.
14. Kapitanovic S, Spaventi R, Vujsic S et al. nm23-H1 gene expression in ovarian tumors-a potential tumor marker. Anticancer Res 1995; 15: 587-590.
15. Barrios CH, de Guedes Neto E, Monteggia P, Fuhrmeister F, Basso A, Siqueira DP. Value of CA 125 as a tumor marker in ovarian carcinomas. Rev Assoc Med Bras 1995; 41: 329-332.
16. Crombach G, Zippel HH, Wurz H. Experiences with CA 125, a tumor marker for malignant epithelial ovarian tumors. Geburtshilfe Frauenheilkd 1985; 45: 205-212.
17. Menon U, Talaat A, Rosenthal AN et al. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. Br J Obst Gynecol 2000; 107: 165-169.
18. Gang Y, Adachi I, Ohkura H et al. CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies. Gan To Kagaku Ryoho 1985; 12: 2379-2386.
19. Stearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat 1998; 52: 239-259.
20. Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 2001; 6: 375-379.
21. Lamerz R. Clinical relevance of tumor markers. Wien Klin Wochenschr 1989; 101: 464-472.
22. Pujol H. Importance of early detection of metastases. Impact on survival and quality of life. Nucl Med Biol 1994; 21:303-315.
23. Nikolic B, Mitrovic A, Lazic J. Meaning of CA 125 in making therapy decision in adnexal inflammatory tumors. Bosn J Basic Med Sci 2006; 6: 3-6.
24. Erdemoglu E, Kamaci M, Ozen S, Sahin HG, Kolusari A. I Ovarian hemangioma with elevated CA125 and ascites mimicking ovarian cancer. Eur J Gynaecol Oncol 2006; 27: 195-196.
25. Terauchi F, Onodera T, Nagashima T et al. Sclerosing stromal tumor of the ovary with elevated CA125. J Obstet Gynaecol Res 2005; 31: 432-435.
26. Kandylis K, Vassilomanotakis M, Baziotis N et al. Diagnostic significance of the tumor markers CEA, CA 15-3 and CA 125 in malignant effusions in breast cancer. Ann Oncol 1990; 1: 435-438.
27. Crawford LV, Pim DC, Butbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982; 30: 403-408.
28. Mack U, Ukena D, Montenarh M, Sybrecht GW. Serum anti-p53 antibodies in patients with lung cancer. Oncol Rep 2000; 7: 669-674.
29. Terauchi F, Okamoto A, Nagashima T et al. Clinical significance of p21 (WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary. Oncol Rep 2005; 14: 363-368.
30. Berker B, Dunder I, Ensari A, Cengiz SD, Simsek E. Prognostic significance of apoptotic index and bcl-2 and p53 expression in epithelial ovarian carcinoma. Eur J Gynaecol Oncol 2002; 23: 505-510.
31. Hartozinska A, Bar JK, Montenarh M, Kartarius S. Relations between immunologically different p53 forms, p21(WAF1) and PCNA expression in ovarian carcinomas. Oncol Rep 2002; 9: 1173-1179.
32. Chang K, Ding I, Kern FG, Willingham MC. Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors. J Histochem Cytochem 1991; 39: 1281-1287.
33. Kupryjanczyk J, Bell DA, Yandell DW, Sculty RE, Thor AD. p53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol 1994; 102: 671-676.
34. Navolanic PM, Steelman LS, McCubrey JA et al. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int J Oncol 2003; 22: 237-252.
35. Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 1999; 9: 125-138.
36. Verri E, Guglielmini P, Puntoni M et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology 2005; 68: 154-161. Epub 2005, Jul 11.
37. Hogdall EV, Christensen L, Kjaer SK et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 2003; 98: 66-73.
38. Riener EK, Arnold N, Kommoss F, Lauinger S, Pfisterer J. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a mutticenter study. Gynecol Oncol 2004; 95: 89-94.
39. Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, HER-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004; 14: 1086-1096.